Compare EVTL & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | LAB |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | 389 |
| Industry | Aerospace | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 257.2M |
| IPO Year | 2021 | 2008 |
| Metric | EVTL | LAB |
|---|---|---|
| Price | $0.35 | $0.72 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $6.99 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 758.9K |
| Earning Date | 08-13-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.59 |
| 52 Week High | $7.35 | $1.72 |
| Indicator | EVTL | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 62.71 |
| Support Level | $0.36 | $0.71 |
| Resistance Level | $0.45 | $0.79 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 8.27 | 90.33 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.